The mechanism research showed that it exhibits anti-tumor activities may be attributed to reactivate p53, ATR and CDKN1A, inhibit BCL6-AKT and BCL6-MEK/ERK cross-talk signaling pathway. The gene discussed is MAP2K7; the disease is neoplasm.